No back seat for a progression event-K-RAS as a therapeutic target in CRC

Genes Dev. 2017 Feb 15;31(4):333-335. doi: 10.1101/gad.297630.117. Epub 2017 Mar 17.

Abstract

KRAS is the most frequently mutated oncogene in human cancer and plays a central, although poorly understood, role in colorectal cancer (CRC) progression. In this issue of Genes & Development, Boutin and colleagues (pp. 370-382) present a new mouse model of CRC in which the expression of oncogenic K-RAS is regulated by doxycycline. Using this model, they demonstrate that continued expression of oncogenic K-RAS is required for the survival of primary and metastatic colon cancers and that oncogenic K-RAS activates TGF-β signaling to promote tumor invasion and metastasis.

Keywords: Apc; Kras; P53; colorectal cancer; invasion; metastasis.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Colorectal Neoplasms / genetics*
  • Colorectal Neoplasms / physiopathology*
  • Disease Models, Animal
  • Disease Progression
  • Doxycycline / pharmacology
  • Gene Expression Regulation, Neoplastic / drug effects
  • Genes, ras / genetics*
  • Signal Transduction / genetics
  • Transforming Growth Factor beta / metabolism

Substances

  • Transforming Growth Factor beta
  • Doxycycline